Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans.

European journal of clinical pharmacology - 1 Sept 2012

Helldén A, Panagiotidis G, Johansson P, Waters N, Waters S, Tedroff J, Bertilsson L

Abstract excerpt

PURPOSE: The influence of the cytochrome P450 enzyme CYP2D6 in the metabolism of the novel dopaminergic stabilizer pridopidine was investigated in healthy Swedish Caucasians. METHODS: Six extensive metabolizers (EM) and six poor metabolizers (PM) of debrisoquine were given a single oral dose of pridopidine (EM, 50 mg; PM, 25 mg). RESULTS: The mean total plasma clearance of pridopidine was 541 and 138 mL/min in EM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Cytochrome P-450 CYP2D6 Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Antagonists

Share to Glomerular Filtration Rate

Share to Half-Life

Share to Intestinal Absorption

Share to Metabolic Clearance Rate

Share to Piperidines

Source

Identifiers

PMID: 22399238
DOI: 10.1007/s00228-012-1248-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans.PMID 22399238Read ↗

Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.Semantic proximity Read ↗

Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.Semantic proximity Read ↗

Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.Semantic proximity Read ↗

Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.Semantic proximity Read ↗

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.Semantic proximity Read ↗

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.Semantic proximity Read ↗

A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone.Semantic proximity Read ↗

Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.Semantic proximity Read ↗

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.Semantic proximity Read ↗

Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.